Laxmi Organic Industries has received a credit rating downgrade from CRISIL Ratings Limited, with the agency revising its long-term bank facilities rating to 'CRISIL AA-/Negative' from 'CRISIL AA/Negative'. The rating agency has simultaneously reaffirmed its 'CRISIL A1+' rating on the company's short-term bank facilities and commercial paper.

Rating Action Details

The rating revision affects Rs.1,170 crore of total bank loan facilities and Rs.150 crore of commercial paper. CRISIL's decision reflects concerns over the company's financial performance trajectory and medium-term outlook.

Financial Performance Decline

The downgrade stems from steeper than anticipated decline in revenue and profitability. Revenue from operations declined 9% to Rs.2,071 crore in the first nine months of fiscal 2026 from Rs.2,276 crore in the corresponding period of fiscal 2025. The decline was driven by significant challenges across both business segments.

The specialty chemical segment, contributing 27% of sales, experienced a sharp 22% revenue decline to Rs.566 crore. Meanwhile, the essential segment, representing 73% of sales, contracted 3% to Rs.1,505 crore. The specialty chemicals decline resulted from steep correction in realization of key products, phase out of a key high-margin agrochemical product, and deferment of deliveries of select products.

Margin Compression Across Segments

Operating margins deteriorated significantly to 4.4% in nine months of fiscal 2026 from 9.5% in the same period of fiscal 2025. The decline affected both key business segments, with specialty chemical margins contracting from 24% to 13%, while essential segment margins compressed from 3% to 1%.

Capital Investment and Future Outlook

The company is executing substantial capital expenditure of over Rs.700 crore in fiscal 2026, with approximately Rs.550 crore allocated to the Dahej plant and the balance towards the Lote plant and maintenance activities. By the nine-month period of fiscal 2026, Laxmi Organic had already incurred capex of over Rs.475 crore, funded through a mix of debt and internal accruals.

Despite current challenges, CRISIL expects revenue to potentially increase to Rs.3,300-3,500 crore over the medium term, driven by stable revenue from existing capacities and additional revenues from newly added capacities at Dahej and Lote facilities.

Financial Risk Profile Remains Stable

The company maintains a healthy capital structure with networth of Rs.1,928 crore as of September 30, 2025, against debt of Rs.330 crore, resulting in gearing of 0.17 times. However, adjusted interest coverage deteriorated to 6.00 times in the first nine months of fiscal 2026 from 18.68 times in the corresponding previous period due to declining profitability.

Market Position and Business Strengths

Laxmi Organic maintains strong market positions across its verticals, commanding approximately 34% market share in ethyl acetate and meeting close to 55% of domestic demand in diketene derivatives. The company serves over 620 customers across diverse end-user industries including pharmaceuticals, agrochemicals, dyes and pigments, with no single customer contributing more than 10% of revenue in fiscal 2025.

The negative outlook reflects sustained deterioration in operating margins and slower than expected recovery in operating efficiency and return on capital employed, while the financial risk profile is expected to remain comfortable over the medium term.

Laxmi Organic Industries Limited has filed a regulatory intimation confirming no deviation in the utilization of Qualified Institutions Placement (QIP) proceeds for the quarter ended December 31, 2025. The company submitted its compliance report to BSE and NSE on February 4, 2026, along with the monitoring agency report issued by India Ratings & Research Private Limited.

QIP Issue Details and Current Status

The company's QIP was conducted from October 5, 2023, to October 10, 2023, raising INR 2,591.21 million through the issuance of 9,625,579 equity shares at INR 269.20 per share. The monitoring agency report confirms that all utilization remains aligned with the objects stated in the placement document dated October 10, 2023.

Project-wise Utilization and Reallocation

The company has made significant progress across its funded projects, with notable completion of the Mahape innovation center. The monitoring report reveals a strategic reallocation of funds following project completion and cost optimization.

Mahape Project Completion and Fund Reallocation

The Mahape innovation center project achieved completion with cost savings of INR 109.58 million against the original estimate. The 2,100 square meter facility is designed to scale R&D efforts in line with growing manufacturing sites and product pipeline. Following project completion, the Board approved reallocation of the saved amount to the Dahej project on October 29, 2025, subsequently ratified by shareholders through postal ballot on December 6, 2025.

Dahej Manufacturing Facility Progress

The Dahej manufacturing facility project continues as an ongoing initiative, with INR 1,511.42 million utilized out of the revised allocation of INR 1,729.24 million. The facility, spread across 84.71 acres in Bharuch, Gujarat, represents the company's expansion strategy to add manufacturing capacity and provide geographic diversification from the existing Mahad facilities.

Deployment of Unutilized Proceeds

The company has deployed the unutilized QIP proceeds of INR 217.82 million in liquid investments to optimize returns while maintaining liquidity for ongoing project requirements.

Note: Total includes unutilized proceeds of INR 217.82 million plus returns of INR 6.75 million

Regulatory Compliance and Monitoring

The monitoring agency report confirms that all statutory requirements under SEBI regulations have been met, with no material deviations observed. The company has obtained necessary government approvals for current project stages, with the Dahej project timeline extended to June 30, 2026, following Board and shareholder approvals. The comprehensive monitoring framework ensures transparent utilization of investor funds in accordance with disclosed objectives.